ReviewNeural regeneration research2019
Neuroinflammation as a target for glaucoma therapy.
Review in Neural regeneration research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 3 syntheses or guidelines pooled it, 126 citations in OpenAlex.
- Protective effect of resveratrol on retinal damage in glaucoma: a systematic review and meta-analysis of preclinical studies.Frontiers in pharmacology · 2024Pooled it
- Pooled it
- The association of toll-like receptor 4 gene polymorphisms with primary open angle glaucoma susceptibility: a meta-analysis.Bioscience reports · 2019Pooled it
- Retinal glial cells in glaucoma and age-related retinal diseases: Inflammatory responses, disease transitions, and translational perspectives.Neural regeneration research · 2026Article
- Pathological P-Selectin Upregulation Promotes Retinal Ganglion Cell Degeneration Accompanied by T-Cell Recruitment in Glaucoma.Investigative ophthalmology & visual science · 2026Article
- Intraocular pressure induced blood retinal barrier compromise in mouse models and human glaucoma.Nature communications · 2026Article
- Liproxstatin-1 Attenuates Retinal Ischemia-Reperfusion Injury by Suppressing EGR1-Mediated Ferroptosis.Antioxidants (Basel, Switzerland) · 2026Article
- Risk of new-onset glaucoma in people with carpal tunnel syndrome: a global-federated, multicenter retrospective cohort study.International journal of medical sciences · 2026Article
- Single-Cell Transcriptome Analysis of the Retina During the Development of Normal Tension Glaucoma in Mice.Inflammation · 2025Article
- Ketorolac, melatonin and latanoprost tri-loaded PLGA microspheres for neuroprotection in glaucoma.Drug delivery · 2025Article
- Neobaicalein Alleviates Retinal Damage via Microglia-Mediated Astrocyte Phenotypic Transformation.Applied biochemistry and biotechnology · 2025Article
- TLR4 deficiency does not alter glaucomatous progression in a mouse model of chronic glaucoma.Scientific reports · 2025Article
- Tauroursodeoxycholic Acid Protects Retinal Ganglion Cells and Reduces Inflammation in Mice Following Optic Nerve Crush.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Evaluating the impact of caloric restriction, body mass index and exercise on primary open-angle glaucoma: A review.European journal of ophthalmology · 2025Review
- Research on neurotrophic factor for glaucoma: a worldwide bibliometric analysis.International journal of ophthalmology · 2025Article
- CD3zeta-mediated modulation of TCR signaling: a novel strategy for neuroprotection in retinal ganglion cell degeneration.Frontiers in cell and developmental biology · 2025Article
- Pro-inflammatory S100A9 contributes to retinal ganglion cell degeneration in glaucoma.Frontiers in immunology · 2025Article
- Network-based hub biomarker discovery for glaucoma.BMJ open ophthalmology · 2024Article
- The Role of Gut Microbiota in the Pathogenesis of Glaucoma: Evidence from Bibliometric Analysis and Comprehensive Review.Bioengineering (Basel, Switzerland) · 2024Review
- Evaluation of Rho kinase inhibitor effects on neuroprotection and neuroinflammation in an ex-vivo retinal explant model.Acta neuropathologica communications · 2024Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pathogenesis of glaucoma is still not fully clarified but a growing body of evidence suggests that neuroinflammation and immune response are part of the sequence of pathological events leading to the optic neuropathy. Indeed, inflammation - involving the activation and proliferation of resident glial cells (astrocytes, Muller cells and microglia) and the release of a plethora of anti- and pro-inflammatory cytokines, chemokines and reactive oxygen species - has been reported as common features in clinical and experimental glaucoma. In the insulted retina, as for other neuronal tissues, pathogenic and reparative aspects coexist in the inflammatory process, with extent and persistency affecting the final outcome. In view of this, therapies aimed at modulating the immune and inflammatory responses may represent a promising approach for limiting the optic nerve damage and the loss of retinal ganglion cells associated with glaucoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.